To ameliorate negative regulation mediated by immune checkpoint molecular expression by tumor cells, immune checkpoint inhibitor (ICI) antibodies blocking the CTLA-4 or PD-1 pathway have been developed. This evidence concerns the gene CTLA4 and neoplasm.